Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Shares Bought by Nuveen Asset Management LLC

Nuveen Asset Management LLC boosted its stake in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) by 46.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 722,155 shares of the company's stock after purchasing an additional 229,746 shares during the quarter. Nuveen Asset Management LLC owned about 1.50% of Mirum Pharmaceuticals worth $29,861,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently added to or reduced their stakes in MIRM. Janus Henderson Group PLC boosted its holdings in Mirum Pharmaceuticals by 2.3% in the fourth quarter. Janus Henderson Group PLC now owns 4,581,642 shares of the company's stock worth $189,481,000 after acquiring an additional 101,358 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in Mirum Pharmaceuticals by 10.8% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,422,729 shares of the company's stock worth $58,831,000 after acquiring an additional 138,623 shares in the last quarter. Geode Capital Management LLC boosted its holdings in Mirum Pharmaceuticals by 0.8% in the fourth quarter. Geode Capital Management LLC now owns 943,344 shares of the company's stock worth $39,016,000 after acquiring an additional 7,147 shares in the last quarter. Clearbridge Investments LLC boosted its holdings in Mirum Pharmaceuticals by 2.0% in the fourth quarter. Clearbridge Investments LLC now owns 907,317 shares of the company's stock worth $37,518,000 after acquiring an additional 18,217 shares in the last quarter. Finally, Lord Abbett & CO. LLC boosted its holdings in Mirum Pharmaceuticals by 5.5% in the fourth quarter. Lord Abbett & CO. LLC now owns 782,354 shares of the company's stock worth $32,350,000 after acquiring an additional 40,986 shares in the last quarter.

Mirum Pharmaceuticals Stock Performance

Shares of NASDAQ:MIRM traded down $0.13 during trading on Tuesday, hitting $43.87. The stock had a trading volume of 293,688 shares, compared to its average volume of 522,522. Mirum Pharmaceuticals, Inc. has a 12-month low of $23.83 and a 12-month high of $54.23. The stock has a market capitalization of $2.17 billion, a price-to-earnings ratio of -21.72 and a beta of 0.95. The company has a quick ratio of 3.15, a current ratio of 3.34 and a debt-to-equity ratio of 1.33. The stock has a 50-day simple moving average of $42.80 and a two-hundred day simple moving average of $44.65.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last announced its quarterly earnings data on Wednesday, May 14th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.05. Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. The firm had revenue of $111.59 million during the quarter, compared to analysts' expectations of $98.47 million. During the same period last year, the business posted ($0.54) earnings per share. The company's revenue for the quarter was up 61.2% compared to the same quarter last year. On average, equities research analysts expect that Mirum Pharmaceuticals, Inc. will post -1.43 earnings per share for the current fiscal year.

Analysts Set New Price Targets

MIRM has been the subject of several recent analyst reports. Raymond James reissued a "strong-buy" rating on shares of Mirum Pharmaceuticals in a report on Tuesday, May 13th. HC Wainwright reissued a "buy" rating and issued a $73.00 price target on shares of Mirum Pharmaceuticals in a report on Monday, May 19th. JMP Securities raised their price target on Mirum Pharmaceuticals from $74.00 to $76.00 and gave the stock a "market outperform" rating in a report on Friday, May 9th. Finally, Robert W. Baird raised their price target on Mirum Pharmaceuticals from $50.00 to $55.00 and gave the stock an "outperform" rating in a report on Thursday, February 27th. Ten research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, Mirum Pharmaceuticals presently has an average rating of "Buy" and a consensus price target of $60.73.

Insider Activity at Mirum Pharmaceuticals

In related news, CEO Christopher Peetz sold 27,279 shares of Mirum Pharmaceuticals stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $44.21, for a total transaction of $1,206,004.59. Following the completion of the transaction, the chief executive officer now directly owns 138,641 shares in the company, valued at approximately $6,129,318.61. This trade represents a 16.44% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Patrick J. Heron purchased 1,335 shares of Mirum Pharmaceuticals stock in a transaction that occurred on Tuesday, March 4th. The shares were bought at an average price of $45.57 per share, with a total value of $60,835.95. Following the completion of the transaction, the director now owns 163,643 shares of the company's stock, valued at $7,457,211.51. This represents a 0.82% increase in their position. The disclosure for this purchase can be found here. Over the last ninety days, insiders sold 92,764 shares of company stock worth $4,109,161. 14.36% of the stock is owned by corporate insiders.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.